HQY vs INVA vs CVS vs WEX vs UNH

For growth investors, Innoviva, Inc.

(INVA) is the stronger pick with 18. 5% revenue growth year-over-year, versus 1. 2% for WEX Inc. (WEX). Innoviva, Inc. (INVA) offers the better valuation at 6. 9x trailing P/E (11. 9x forward), making it the more compelling value choice. Analysts rate HealthEquity, Inc. (HQY) a "Buy" — based on 27 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Innoviva, Inc.

(INVA) is the cheapest at 6. 9x versus CVS Health Corporation at 62. 8x. On forward P/E, WEX Inc. is actually cheaper at 7. 4x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: HealthEquity, Inc. wins at 0. 26x versus Innoviva, Inc. 's 1. 15x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, Innoviva, Inc.

(INVA) delivered a total return of +94. 4%, compared to -26. 5% for WEX Inc. (WEX). Over 10 years, the gap is even starker: HQY returned +228. 2% versus CVS's +3. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), CVS Health Corporation (CVS) is the lower-risk stock at 0.

05β versus WEX Inc. 's 1. 16β — meaning WEX is approximately 2196% more volatile than CVS relative to the S&P 500. On balance sheet safety, HealthEquity, Inc. (HQY) carries a lower debt/equity ratio of 2% versus 4% for WEX Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Innoviva, Inc.

(INVA) is pulling ahead at 18. 5% versus 1. 2% for WEX Inc. (WEX). On earnings-per-share growth, the picture is similar: Innoviva, Inc. grew EPS 816. 7% year-over-year, compared to -62. 0% for CVS Health Corporation. Over a 3-year CAGR, HQY leads at 15. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Innoviva, Inc.

(INVA) is the more profitable company, earning 63. 8% net margin versus 0. 4% for CVS Health Corporation — meaning it keeps 63. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: INVA leads at 38. 5% versus 2. 6% for CVS. At the gross margin level — before operating expenses — INVA leads at 72. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, HealthEquity, Inc. (HQY) is the more undervalued stock at a PEG of 0. 26x versus Innoviva, Inc. 's 1. 15x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, WEX Inc. (WEX) trades at 7. 4x forward P/E versus 21. 2x for HealthEquity, Inc. — 13. 8x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for INVA: 65. 2% to $37. 67.

In this comparison, CVS (3.

1% yield), UNH (2. 4% yield) pay a dividend. HQY, INVA, WEX do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, CVS Health Corporation (CVS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

05), 3. 1% yield). Both have compounded well over 10 years (CVS: +3. 5%, WEX: +60. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (HQY (Healthcare) and INVA (Healthcare) and CVS (Healthcare) and WEX (Technology) and UNH (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: HQY is a small-cap quality compounder stock; INVA is a small-cap high-growth stock; CVS is a mid-cap income-oriented stock; WEX is a small-cap deep-value stock; UNH is a large-cap quality compounder stock. CVS, UNH pay a dividend while HQY, INVA, WEX do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.